Abstract: The present disclosure provides an experiment platform for simulating fire in an underground traffic conversion channel, including: a model body configured to simulate fire in the an underground traffic conversion channel; a burner connected to the model body and configured to generate smoke; and a smoke imaging system including laser sheet light sources and image recording devices configured to record smoke distribution images. The laser sheet light sources are in the model body, and plane laser light emitted by the laser sheet light sources is parallel to a flow direction of the smoke. The image recording devices are in one-to-one correspondence to the laser sheet light sources and are arranged outside an observation window of the model body. One laser sheet light source and one image recording device corresponding thereto each have a filter configured to filter out laser light of a same wavelength.

Abstract: The present disclosure provides an experiment platform for simulating fire in an underground traffic conversion channel, including: a model body configured to simulate fire in the an underground traffic conversion channel; a burner connected to the model body and configured to generate smoke; and a smoke imaging system including laser sheet light sources and image recording devices configured to record smoke distribution images. The laser sheet light sources are in the model body, and plane laser light emitted by the laser sheet light sources is parallel to a flow direction of the smoke. The image recording devices are in one-to-one correspondence to the laser sheet light sources and are arranged outside an observation window of the model body. One laser sheet light source and one image recording device corresponding thereto each have a filter configured to filter out laser light of a same wavelength.

Abstract: A compatible inductor-type circuit structure with direct input from commercial power includes a substrate and a light-source control-loop device. The light-source control-loop device is disposed on the substrate and includes a constant current circuit, plural light source modules, a switch, a commercial power simulation circuit, a high voltage protection circuit, plural bridge rectifier circuits and a limited current protection circuit. The constant current circuit, the light source modules, the switch, the commercial power simulation circuit, the high voltage protection circuit, the bridge rectifier circuits and the limited current protection circuit are connected together electrically. By the abovementioned structures, a luminaire can be installed directly on any lamp holder, without considering whether to remove the ballast. The circuit structure can be compatible with a dedicated LED lamp holder or a lamp holder activated by a ballast, thereby facilitating the usage.

Abstract: A compatible inductor-type circuit structure with direct input from commercial power includes a substrate and a light-source control-loop device. The light-source control-loop device is disposed on the substrate and includes a constant current circuit, plural light source modules, a switch, a commercial power simulation circuit, a high voltage protection circuit, plural bridge rectifier circuits and a limited current protection circuit. The constant current circuit, the light source modules, the switch, the commercial power simulation circuit, the high voltage protection circuit, the bridge rectifier circuits and the limited current protection circuit are connected together electrically. By the abovementioned structures, a luminaire can be installed directly on any lamp holder, without considering whether to remove the ballast. The circuit structure can be compatible with a dedicated LED lamp holder or a lamp holder activated by a ballast, thereby facilitating the usage.

Abstract: Methods and cosmetic compositions for conditioning the skin, utilizing as active ingredients selected compounds structurally related to astragenols, cycloastragenols, and/or protopanaxatriols, are provided. Such compounds include those of formulas (I), (II) and (III) described herein.

Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Abstract: The present invention relates to an area light source module with multipoint chip-on-board. With separatively-disposed multipoint chip conductive layer portions and conductive wiring layer portions disposed between multipoint chip conductive layer portions of a substrate body, it can be more flexible for the wire-bonding and conductive connection and the circuit design of conductive metal wire bodies to be formed in serial and parallel connections, and also the whole assembly structure and the manufacturing process can be simplified, thereby facilitating the heat dissipation efficiency of light source chip bodies to increase the illumination efficiency and providing stable structural configuration and illumination.

Abstract: A method of treating, preventing, or ameliorating a pathological condition associated with a melatonin receptor in a mammal by using a pharmaceutical composition containing a compound of formula (I) as a ligand interacting with the melatonin receptor, R1, R2, R3, R4 and R7 are independently H, halo, alkyloxyl, alkyl or hydroxyl, provided that one of R1, R2, R3 and R7 is X—(CH2)n—R8; R5 is alkyl or arylalkyl; R6 is H or alkyl; X is a bond, O, S, SO, SO2, CO or NH; n=0-10; R8 is alkenyl, substituted or unsubstituted aryl, NR9R10, or OR9; R9 is H, substituted or unsubstituted arylmethyl, or alkenyl; and R10 is H or alkyl.

Abstract: A resilient protective wrap usable to wrap a body part of a user for protection against injury includes at least one resilient fabric layer that is stretchable at least in one direction, and an open cell water-based polyurethane foam laminated on the resilient fabric layer and made from a material including an aqueous dispersion of polyurethane. The polyurethane foam has a thickness of at least 1 mm, a largest elongation ranging from 200%-450%, a modulus of elasticity ranging from 2 to 7 kgf/cm2, a tensile strength of at least 4 kgf/cm2, and a density ranging from 180-600 g/l.

Abstract: A resilient protective wrap usable to wrap a body part of a user for protection against injury includes at least one resilient fabric layer that is stretchable at least in one direction, and an open cell water-based polyurethane foam laminated on the resilient fabric layer and made from a material including an aqueous dispersion of polyurethane. The polyurethane foam has a thickness of at least 1 mm, a largest elongation ranging from 200%-450%, a modulus of elasticity ranging from 2 to 7 kgf/cm2, a tensile strength of at least 4 kgf/cm2, and a density ranging from 180-600 g/l.

Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Abstract: A method of treating, preventing, or ameliorating a pathological condition associated with a melatonin receptor in a mammal by using a pharmaceutical composition containing a compound of formula (I) as a ligand interacting with the melatonin receptor, R1, R2, R3, R4 and R7 are independently H, halo, alkyloxyl, alkyl or hydroxyl, provided that one of R1, R2, R3 and R7 is X—(CH2)n—R8; R5 is alkyl or arylalkyl; R6 is H or alkyl; X is a bond, O, S, SO, SO2, CO or NH; n=0-10; R8 is alkenyl, substituted or unsubstituted aryl, NR9R10, or OR9; R9 is H, substituted or unsubstituted arylmethyl, or alkenyl; and R10 is H or alkyl.

Abstract: The present invention relates to methods for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The method and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin aliments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin aliments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Abstract: A substrate has a bonding region and a sensing region. A first dielectric layer is formed overlying the substrate and has a dielectric island surrounded by a ring-shaped trench. A first conductive layer is formed in the ring-shaped trench of the first dielectric layer. A passivation layer is formed overlying the first dielectric layer and has an opening, in which the opening corresponds to the bonding region and the sensing region and exposes the dielectric island and a part of the first conductive layer. A second conductive layer covers the opening of the passivation layer and is electrically connected to the first conductive layer.

Abstract: A substrate has a bonding region and a sensing region. A first dielectric layer is formed overlying the substrate and has a dielectric island surrounded by a ring-shaped trench. A first conductive layer is formed in the ring-shaped trench of the first dielectric layer. A passivation layer is formed overlying the first dielectric layer and has an opening, in which the opening corresponds to the bonding region and the sensing region and exposes the dielectric island and a part of the first conductive layer. A second conductive layer covers the opening of the passivation layer and is electrically connected to the first conductive layer.

Abstract: A substrate has a bonding region and a sensing region. A first dielectric layer is formed overlying the substrate and has a dielectric island surrounded by a ring-shaped trench. A first conductive layer is formed in the ring-shaped trench of the first dielectric layer. A passivation layer is formed overlying the first dielectric layer and has an opening, in which the opening corresponds to the bonding region and the sensing region and exposes the dielectric island and a part of the first conductive layer. A second conductive layer covers the opening of the passivation layer and is electrically connected to the first conductive layer.

Abstract: A substrate has a bonding region and a sensing region. A first dielectric layer is formed overlying the substrate and has a dielectric island surrounded by a ring-shaped trench. A first conductive layer is formed in the ring-shaped trench of the first dielectric layer. A passivation layer is formed overlying the first dielectric layer and has an opening, in which the opening corresponds to the bonding region and the sensing region and exposes the dielectric island and a part of the first conductive layer. A second conductive layer covers the opening of the passivation layer and is electrically connected to the first conductive layer.

Abstract: The present invention concerns novel G protein chimeras, nucleotide sequences encoding same, host cells transformed or transfected with same, methods of determining GPCR response to a molecule, and kits for same.